Response to sorafenib treatment in advanced metastatic thyroid cancer.

Abstract

OBJECTIVE:

To investigate the efficacy of sorafenib in progressive radioiodine resistant metastatic thyroid carcinoma.

SUBJECTS AND METHODS:

Off-label observational study. Sorafenib 400 mg twice daily was evaluated. Therapy duration was 12 ± 3 months (range 6-16 months).

RESULTS:

Eight patients were included (seven papillary, one insular variant). The eight patients meeting study criteria received sorafenib 400 mg orally twice a day until disease progression or unacceptable toxicity developed. One patient showed a partial response with tumor regression of -35%, six months after the beginning of the treatment; five patients exhibited stable disease and two patients had progressive disease and died. Thyroglobulin decreased within 4 weeks in all patients by 50% ± 23%. Adverse events: one patient had heart failure, and recovered after sorafenib withdrawal. However, she died five months later of sudden death.

CONCLUSION:

These data suggest a possible role for sorafenib in the treatment of progressive metastatic DTC. Adverse event are usually manageable, but severe ones may appear and these patients should be strictly controlled.

• Authors: Fabian Pitoia
• Journal: Arquivos brasileiros de endocrinologia e metabologia (Arq Bras Endocrinol Metabol) Vol. 58 Issue 1 Pg. 37-41 (Feb 2014) ISSN: 1677-9487 [Electronic] Brazil
• PMID: 24728162 (Publication Type: Journal Article, Observational Study)

Chemical References

• Antineoplastic Agents
• Iodine Radioisotopes
• Phenylurea Compounds
• Niacinamide
• Thyroglobulin
• Sorafenib

Topics

• Aged
• Antineoplastic Agents (adverse effects, therapeutic use)
• Bone Neoplasms (secondary)
• Carcinoma, Papillary (drug therapy, pathology, radiotherapy, secondary)
• Compassionate Use Trials
• Female
• Follow-Up Studies
• Heart Failure (chemically induced)
• Humans
• Iodine Radioisotopes (therapeutic use)
• Lung Neoplasms (secondary)
• Male
• Middle Aged
• Niacinamide (adverse effects, analogs & derivatives, therapeutic use)
• Phenylurea Compounds (adverse effects, therapeutic use)
• Response Evaluation Criteria in Solid Tumors
• Sorafenib
• Thyroglobulin (blood)
• Thyroid Neoplasms (drug therapy, pathology, radiotherapy)
• Treatment Outcome